Cellular and molecular mechanisms driving cardiac tissue fibrosis: On the precipice of personalized and precision medicine.
Cardiovasc Pathol
; 71: 107635, 2024.
Article
em En
| MEDLINE
| ID: mdl-38508436
ABSTRACT
Cardiac fibrosis is a significant contributor to heart failure, a condition that continues to affect a growing number of patients worldwide. Various cardiovascular comorbidities can exacerbate cardiac fibrosis. While fibroblasts are believed to be the primary cell type underlying fibrosis, recent and emerging data suggest that other cell types can also potentiate or expedite fibrotic processes. Over the past few decades, clinicians have developed therapeutics that can blunt the development and progression of cardiac fibrosis. While these strategies have yielded positive results, overall clinical outcomes for patients suffering from heart failure continue to be dire. Herein, we overview the molecular and cellular mechanisms underlying cardiac tissue fibrosis. To do so, we establish the known mechanisms that drive fibrosis in the heart, outline the diagnostic tools available, and summarize the treatment options used in contemporary clinical practice. Finally, we underscore the critical role the immune microenvironment plays in the pathogenesis of cardiac fibrosis.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrose
/
Medicina de Precisão
/
Miocárdio
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cardiovasc Pathol
Assunto da revista:
ANGIOLOGIA
/
CARDIOLOGIA
/
PATOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Canadá